NEW YORK – Healthcare artificial intelligence firm Tempus announced earlier this week the acquisition of Akesogen, the owner of a commercial laboratory and provider of genomics and clinical trial precision medicine services.
Tempus said that the acquisition strengthens its expansion into disease areas outside of cancer and provides it with strategic capabilities in addition to those provided by its Chicago laboratory.
Financial and other terms of the deal were not disclosed.
Tempus noted that Akesogen's CLIA-compliant and CAP-accredited lab provides a range of testing services, including for inherited risk of cancer, microbiome profiling, whole-genome genotyping, and epigenomic methylation profiling. Further, its services include providing high-throughput biomarker profiling, and microarray, sequencing, genomics, microbiome, and epigenomics analysis utilizing different types of markers.
Tempus CEO and Founder Eric Lefkofsky said in a statement that the acquired firm's "breadth of capabilities strategically complement our own." With Akesogen, Tempus anticipates "bringing the power of data and artificial intelligence to healthcare," he said.
Tempus said it has a large library of clinical and molecular data and an operating system to make the data accessible and useful. Physicians can make data-driven decisions to facilitate discovery, development, and delivery of optimized therapeutic options for patients.